In recent years, the development of dual or multi‐targeted inhibitors has captured extensive attention of research for treating of malignancies. In this paper, three‐dimensional quantitative structure‐activity relationship and docking studies were performed on 87 pyrazolo[3,4‐d]pyrimidines as dual Src/Abl inhibitors. The appropriate binding orientations and conformations of these compounds interacting with both Src and Abl kinases were revealed by docking studies, and the established optimum CoMFA models yielded q²=0.856, R²=0.966 for Src and q²=0.869, R²=0.974 for Abl, and the best CoMSIA models gave q²=0.877, R²=0.979 for Src and q²=0.885, R²=0.982 for Abl. Systemic external validations further confirm the satisfactory predictive power of these models, producing R²_pred values of 0.872 and 0.865 for Src, 0.876 and 0.867 for Abl, r²_m values of 0.832 and 0.928 for Src, 0.838 and 0.904 for Abl, respectively. In addition, through a comparison between 3D‐QSAR contour maps and docking results, it is revealed that the hydrophobic and electrostatic interactions of compounds play significant roles for the inhibitory activity against both Src and Abl kinases. Some structural factors influencing the activities of these compounds were discussed in detail. The key amino acids impacting the receptor‐ligand interactions have been identified. These theoretical results can offer useful references for designing novel potential dual Src/Abl inhibitors.

Publications with shared reference:

0 publications found